GHK-Cu Side Effects: Topical vs Injected, and What Is Documented

This page separates GHK-Cu side effects that were documented from those that are only reported, by route. The GHK-Cu guide covers mechanism, the injection dosage page covers the protocols people report, and peptide side effects covers the class. For the topical form, see topical GHK-Cu. Everything here is research-use information, not medical advice.

GHK-Cu side effects by route

The frequency language for the injected route is deliberately absent. Nobody has counted, and a page that gives percentages for it is inventing them.

What the human evidence covers

Mulder and colleagues ran a multicentre, randomised, evaluator-blinded, placebo-controlled study of a GHK-Cu gel on diabetic neuropathic foot ulcers, framed as a safety and effectiveness study. Ulcer infections were 7 percent against 34 percent on vehicle (Mulder 1994). Miller and colleagues randomised patients after CO2 laser resurfacing to a regimen with or without GHK-Cu and found no objective difference between groups in the 13 who completed it (Miller 2006). Neither abstract gives adverse event numbers. A 2026 randomised split-face study of a 2% GHK-Cu serum on eyebrows, 18 adults, twice daily for 12 weeks, reported no serious adverse effects or allergic reactions (Bo 2026); its abstract gives no numeric effect sizes.

For injection, the only published human series used GHK-Cu as one of six ingredients in an intradermal scalp mix, open label, in 1,000 patients, reported as well tolerated (Kapoor and Shome 2018). That says nothing about GHK-Cu alone or about subcutaneous systemic use. A 2026 review calls the clinical evidence sparse and notes that no formal absorption and clearance study of the intact complex has been reported (Mateescu 2026). Animal work is consistent with a benign profile at the doses used (mouse lung injury, Park 2016; mouse silicosis, Bian 2024), but animal tolerability is not a human safety study.

What is only reported

Injection sting. GHK-Cu is widely reported to burn on injection. There is no published explanation; candidates are the copper ion, the pH and the concentration, and none has been tested against the others. People describe diluting the dose into a larger volume and injecting slowly. The dosage page has the reconstitution table.

Blue tint. Copper(II) complexes are blue to violet, and a small injected volume can show through pale skin for a few hours. It is the compound's colour, not a bruise.

Fatigue, headache and mood. A minority of people report feeling flat or headachy in the first days of a block, and a few report a lift in mood. There is no incidence data and no established mechanism. The discoverer's reviews describe anti-inflammatory and gene-expression effects (Pickart and Margolina 2018), which makes a systemic effect plausible, and plausible is as far as the evidence goes.

Topical "copper uglies". Some users report bumps or rougher texture over the first weeks of a copper serum. No published study describes it. Formulation, a clash with vitamin C or acids, and over-use are the usual suspects, and it typically resolves on stopping.

The copper question

GHK-Cu is about 16 percent copper by mass. An injection carries copper that skips the intestinal regulation applied to dietary copper. The NIH notes that regularly taking in excess copper can cause liver damage, and the 2026 review says the dominant long-term concern is cumulative copper burden with chronic or large-area topical use or repeated injection, and that oral dietary limits cannot be converted into parenteral limits.

The Bureau's arithmetic, not a trial result. On these numbers a 2 mg dose adds about a third of a day's dietary allowance and a thirtieth of the oral upper limit, which is not alarming, but the limits were set for oral intake and nobody has studied months of injected copper. Copper is cleared through the liver (bile), which is why long injected blocks without breaks deserve more caution than short ones.

A separate issue is the product. GHK binds copper at a defined one-to-one ratio, and a vendor can sell GHK with too little or too much copper under one label. An HPLC purity line shows the peptide fraction, not the copper content. Only a certificate of analysis that reports copper, or elemental analysis, tells you what is in the vial. See peptide testing for how to read one.

Who should not use GHK-Cu

• Wilson's disease or another copper-handling disorder. The NIH lists Wilson's disease as a condition of copper overload. Adding copper by any route works against its management. Ask a clinician.
• Pregnancy and breastfeeding. No data by any route.
• Known copper contact allergy, for the topical route.
• Active cancer or a recent history. A computational Connectivity Map analysis predicted GHK would reverse a metastasis-prone gene signature in colorectal cancer (Hong 2010), a prediction and not a treatment result. The discoverer's reviews describe effects on blood vessel and nerve outgrowth (Pickart and Margolina 2018). Nobody has resolved how these fit in a person, so it is a question for an oncologist.

Is GHK-Cu FDA approved? Dated status

The Bureau found no FDA-approved drug product containing GHK-Cu; it appears in cosmetics as Copper Tripeptide-1. The regulatory question people actually mean is compounding, and it moved in 2026. FDA's reason when GHK-Cu was in category 2 was that the injectable form "may pose risk for immunogenicity due to the potential for aggregation and peptide-related impurities. There are limited data in humans."

A committee vote is advisory, and leaving category 2 does not make a substance eligible for compounding. See also the research peptide legal status guide and the July 2026 advisory committee vote on other peptides. Status as of 27 October 2026; check FDA's pages for later changes.

Dose conversions for the vial you hold are in the Peptulator GHK-Cu calculator.

Frequently asked questions

What are the side effects of GHK-Cu?

For topical GHK-Cu, the controlled trials the Bureau found reported fewer ulcer infections in diabetic foot ulcers, no objective difference after laser resurfacing, and no serious adverse effects in a 12 week eyebrow serum study. For injected GHK-Cu on its own, no human safety trial exists. Reports describe a sting at the site, a temporary blue tint, bruising, and in a minority fatigue or headache, none of them counted in a study.

Is GHK-Cu safe to inject?

Nobody knows, because no human trial of GHK-Cu alone by injection has been published. A 2026 review calls the clinical evidence sparse and says no formal absorption and clearance study of the intact complex has been reported. In mice, parenteral GHK-Cu showed no significant systemic toxicity in a silicosis model, which is animal data and not a human safety study.

How much copper is in a GHK-Cu injection?

GHK-Cu is about 16 percent copper by mass, so a 1 mg dose carries about 0.16 mg of copper and a 2 mg dose about 0.3 mg. Two mg daily for 8 weeks adds up to about 18 mg. For comparison, the NIH lists the adult recommended intake at 900 micrograms a day and the tolerable upper intake at 10 mg a day, both set for oral intake.

Who should not use GHK-Cu?

Anyone with Wilson's disease or another disorder of copper handling should not add copper by any route without a clinician, because the compound delivers copper. There is no pregnancy or breastfeeding data by any route. Anyone with a known copper contact allergy should avoid the topical forms.

Is GHK-Cu FDA approved or banned?

The Bureau found no FDA-approved drug product containing GHK-Cu. Its compounding status has changed in 2026: FDA's category 2 page, current as of 22 April 2026, lists injectable GHK-Cu among substances nominated but withdrawn, and FDA says it intends to consult its advisory committee on GHK-Cu before the end of February 2027. It is sold for laboratory research under research use labelling.

Sources

1. Mulder GD et al. Enhanced healing of ulcers in patients with diabetes by topical treatment with GHK copper. Wound Repair Regen 1994
2. Miller TR et al. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg 2006
3. Bo et al. The Efficacy of 2% Copper Peptide (GHK-Cu) Serum for Eyebrow Hypotrichosis. Procedia of Multidisciplinary Research 2026
4. Kapoor R, Shome D. Intradermal injections of a hair growth factor formulation: first-in-man pilot study. J Cosmet Laser Ther 2018
5. Mateescu DM et al. GHK-Cu as a bioactive metallopeptide and drug-delivery cargo. Pharmaceutics, 27 Aug 2026
6. Park JR et al. The tri-peptide GHK-Cu complex ameliorates lipopolysaccharide-induced acute lung injury in mice. Oncotarget 2016
7. Bian Y et al. The GHK-Cu tripeptide complex attenuates lung inflammation and fibrosis in silicosis by targeting peroxiredoxin 6. Redox Biol 2024
8. Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci 2018
9. Pickart L. The human tri-peptide GHK and tissue remodeling. J Biomater Sci Polym Ed 2008
10. Hong Y et al. A 'metastasis-prone' signature for early-stage colorectal cancer patients and its implications for possible therapeutics. Clin Exp Metastasis 2010
11. Purello D'Ambrosio F et al. Systemic contact dermatitis to copper-containing IUD. Allergy 1996
12. Goodwin Law. FDA signals potentially evolving stance toward compounding of certain peptides, May 2026
13. NIH Office of Dietary Supplements. Copper fact sheet
14. FDA. Certain bulk drug substances for use in compounding that may present significant safety risks (category 2), current as of 22 April 2026
15. FDA. 503A categories of bulk drug substances, updated 14 May 2026